Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: warfarin response + genetic variation + warfarin  Related to the article below (Last Update: 7/8/2008)

Pharmacogenomics: When drug treatment becomes personalized medicine
MayoClinic.com - Jun 27, 2008
The CYP450 test can be used to determine dosing and effect of certain antidepressant medications, anticoagulants such as warfarin, proton pump inhibitors ...
Source: Google News

Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin … -
MK Higashi, DL Veenstra, LM Kondo, AK Wittkowsky, … - JAMA, 2002 - Am Med Assoc
... 1 In addition, genetic variation of the hepatic microsomal enzyme CYP2C9, the ... warfarin,
may lead to significant differences in patient response to warfarin. ...

Common VKORC1 and GGCX polymorphisms associated with warfarin dose -
M Wadelius, LY Chen, K Downes, J Ghori, S Hunt, N … - The Pharmacogenomics Journal, 2005 - nature.com
... We attempt to evaluate whether common genetic variation in the vitamin K cycle ... the
first time, explanation of almost 60% of variable response to warfarin. ...

[PDF] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk … -
GP Aithal, CP Day, PJ Kesteven, AK Daly - Lancet, 1999 - bcgsc.ca
... genetics of warfarin metabolism and the identification of genetic factors that
contribute to the individuality of the warfarin dose response may help ...
-

… II, VII, IX, and X; proteins S and C; and {gamma}-glutamyl carboxylase) gene variants with warfarin … -
E Shikata, I Ieiri, S Ishiguro, H Aono, K Inoue, T … - Blood, 2004 - bloodjournal.hematologylibrary.org
... interpatient variation is attributable to genetic variation, and the ... than that of
(R)-warfarin, about 3 ... a significant influence on the anticoagulant response. ...

Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin -
MW Linder - Clinica Chimica Acta, 2001 - Elsevier
... of genetic variation in Warfarin pharmacokinetics is reviewed and the potential
for similar genetic mechanism impacting on the pharmacodynamic response in man ...

Interindividual variability in sensitivity to warfarin-Nature or nurture? -
R Loebstein, H Yonath, DP MSc, SA PhD, MR PhD, A … - Clinical Pharmacology & Therapeutics, 2001 - nature.com
... because the WSI coefficient of variation was greater ... Genetic analysis of the human
cytochrome P450 CYP2C9 ... and risk factors for an excessive warfarin response. ...

Natural selection mapping of the warfarin-resistance gene -
MH Kohn, HJ Pelz, RK Wayne - Proceedings of the National Academy of Sciences of the …, 2000 - pubmedcentral.nih.gov
... 32-cM region that includes the warfarin-resistance gene (Rw ... and to study the underlying
genetic architecture of ... example of an evolutionary response to natural ...

Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms -
MW Linder, S Looney, JE Adams, N Johnson, D … - Journal of Thrombosis and Thrombolysis, 2002 - Springer
... Page 6. 232 Linder et al. 7. Narayanan MN, Lucas SB. A genetic algorithm to improve
a neural network to predict a patient response to warfarin. ...

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin -
BF Gage, C Eby, PE Milligan, GA Banet, JR Duncan, … - Thromb Haemost, 2004 - schattauer.de
... Genetic polymorphism in exon 4 of cyto- chrome P450 CYP2C9 may be associated with
warfarin sensitivity ... Aging and the anticoagulant response to warfarin therapy ...

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors -
M Wadelius, K S?rlin, O Wallerman, J Karlsson, QY … - The Pharmacogenomics Journal, 2004 - nature.com
... 1 Interindividual variation in the response to warfarin and a ... for metabolism of the
active S-warfarin, 7,13 which renders the genetic variation of this ...

Source: Google Scholar
 
 

Genetic variation alters response to Warfarin

 
 
The anticoagulant drug Warfarin ( Coumadin ) is commonly prescribed to prevent harmful clotting after a heart attack, stroke, or major surgery. But the proper dose of Warfarin can vary greatly and can be hard to predict.
Some of this variability may boil down to a recently identified gene involved in blood clotting.

Researchers at the University of Washington in Seattle and Washington University in St. Louis found that variations in a gene involved in blood clotting may explain why certain people require a lower or higher dose of Warfarin to get its full benefits.
.
The study, part of the NIH Pharmacogenetics Research Network, was supported by three components of the National Institutes of Health ( NIH ): the National Institute of General Medical Sciences ( NIGMS ); the National Heart, Lung, and Blood Institute ( NHLBI ); and the National Institute of Environmental Health Sciences ( NIEHS ).

“ This research points to the value of pharmacogenetics, the study of how genetic variations can alter people’s responses to medicines, ” said NIH Director Elias A. Zerhouni. “ It shows one important way in which we are beginning to apply knowledge about the human genome for treating disease and improving human health.”

“ There is a narrow window between too much and too little effect,” explained Rettie. “A small change in dose can have quite a large effect on blood processes.”
For example, too high of a dose of Warfarin can result in excessive bleeding while too little of a dose could allow dangerous blood clots to form.

Physicians primarily use information about a patient’s sex, age, weight, and medical history to set the initial Warfarin dose.
However, it can take several months of clinic visits and needle pricks to determine an individual’s ideal dose.
Scientists know that variations in a gene encoding the CYP2C9 enzyme that metabolizes Warfarin account for about 10 percent of the difference in people’s responses to the drug, but tests for these genetic variations are not routinely performed.

Rettie and his colleague Mark J. Rieder, of the University of Washington’s Department of Genome Sciences and first author of the paper, wanted to better understand the genetic basis for variability in Warfarin response. “ If you want to predict dose, you need to know more about the genes that control variability,” explained Rieder.

Researchers focused on another gene: vitamin K epoxide reductase ( VKORC1 ), which makes a protein that helps control clotting and is the key target of Warfarin. They analyzed the VKORC1 gene’s DNA sequence in 186 patients on a stabilized dose of Warfarin and searched for common DNA variations responsible for changing the gene’s activity and the amount of protein it made.

“ We did find genetic variations that appear to turn up the gene or turn it down,” said Rieder.

By matching the genetic variations to actual Warfarin doses, the scientists discovered that people with a particular variation of the VKORC1 gene generally took similar doses of Warfarin.

The genetic variations divided patients into three main groups: low, high, and intermediate dose.
The intermediate group included people with a combination of the low- and high-dose gene versions.
These results suggest that information about the VKORC1 gene could predict a person’s response to the anti-clotting drug.

“ We found that 25 percent of the variance in Warfarin dose is due to this one gene,” said Rettie.
“ This is possibly the single biggest contributor to variability in people’s responses to the drug and could be a central factor in setting the initial dose.”

The team also learned that certain population groups tended to have a higher prevalence of a particular VKORC1 variation.
While Asian Americans generally had the low-dose variation, African Americans had the high-dose version. European Americans fell in the middle.

“ What we’ve done is the basic science,” said Rettie. “ This complete genetic analysis of VKORC1 provides the mechanistic framework and impetus for prospective studies in a clinical setting. Such studies could determine if knowledge of genetic variability truly improves patient treatment with this frontline anticoagulant drug.”

Source: The New England Journal of Medicine, 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News9A ;

 

ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page